DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 30, 32, 35, 38-39, 41, 43-54 and 159-163 are pending. Claims 39 and 44-45 are rejected. Claims 30, 32, 35, 38, 41, 43, 46-54 and 159-163 are allowed.
Priority
This application claims benefit to PRO 63/544,054 filed 10/13/2023 and PRO 63/517,715 filed 08/04/2023.
Information Disclosure Statement
The information disclosure statement (IDS) dated 06/02/2026 has been considered.
Election/Restrictions
Applicant's election of the compound species
PNG
media_image1.png
152
257
media_image1.png
Greyscale
and the cancer species bran cancer (glioblastoma multiforme) without traverse in the reply filed on August 11, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Claims 30, 32, 35, 38-39, 41, 43-54, 159 and 161-163 read on Applicant' s species election. Examination of the elected invention was conducted in accordance with the MPEP 803.02.
The elected species is allowable in view of the prior art; therefore, examination of the Markush-type claim has been extended to the full scope of Formula I-aa.
Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
Claim Rejections - 35 USC § 112(a)
The following is a quotation of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claims 44 and 45 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for causing death of MGMT negative cancer cells, does not reasonably provide enablement for prevention and/or treatment of cancer in general. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention as claimed. Accordingly, the method of claims 44 and 45 are not enabled.
Nature of the invention:
The invention is drawn to a method of preventing or treating cancer comprising administration of a compound of Formula I-aa:
PNG
media_image2.png
208
255
media_image2.png
Greyscale
, as recited in instant claim 1.
Breadth of the invention:
The scope of the claimed invention is very broad, as it is drawn to administration of any of the numerous compounds encompassed by a compound of Formula I-aa as instantly recited to prevent or treat cancer.
State of the prior art and predictability in the art:
No compound has ever been found to prevent or treat cancers of all types generally. Since this assertion is contrary to what is known in medicine, proof must be provided that this revolutionary assertion has merits. The existence of such a “silver bullet” is contrary to our present understanding of oncology. The state of the art is not indicative of any pharmaceutical agents that are useful in the treatment of cancer generally. At Page 1004, Cecil Textbook of Medicine states that “each specific type has unique biologic and clinical features that must be appreciated for proper diagnosis, treatment and study”. Different types of cancers affect different organs and have different methods of growth and harm to the body. Also see In re Buting, 163 USPQ 689 (CCPA 1969), wherein ‘evidence involving a single compound and two types of cancer, was held insufficient to establish the utility of the claims directed to disparate types of cancers’. Thus, it is beyond the skill of oncologists today to get an agent to be effective against cancers generally.
A similar statement appears at In re Application of Hozumi et. al., 226 USPQ 353: “In spite of the vast expenditure of human and capital resources in recent years, no one drug has been found which is effective in treating all types of cancer. Cancer is not a simple disease, nor is it even a single disease, but a complex of a multitude of different entities, each behaving in a different way”. There are compounds that treat a modest range of cancers, but no one has ever been able to figure out how to get a compound to be effective against cancer generally, or even a majority of cancers.
The attempts to find compounds to prevent or treat various cancers arguably constitute the single most massive enterprise in all of pharmacology. This has not resulted in finding any treatment for tumors generally. This is because it is now understood that there is no “master switch” for cancers generally; cancers arise from a bewildering variety of differing mechanisms. Even the most broadly effective antitumor-agents are only effective against a small fraction of the vast number of different cancers known. This is true in part because cancers arise from a wide variety of sources, primarily a wide variety of failures of the body’s cell growth regulatory mechanisms, but also such external factors such as viruses (an estimated at least 20% are of viral origin e.g. Human papillomavirus, EBV, Hepatitis B and C, HHV-8, HTLV-1 and other retroviruses, and quite possibly Merkel cell polyomavirus, and there is some evidence that CMV is a causative agent in glioblastoma), exposure to chemicals such as tobacco tars, excess alcohol consumption (which causes hepatic cirrhosis, an important cause of HCC), ionizing radiation, and unknown environmental factors.
Similarly, In re Novak, 134 USPQ 335, 337-338 says “unless one with ordinary skill in the art would accept those allegations as obviously valid and correct, it is proper for the examiner to ask for evidence which substantiates them.” There is no such evidence in this case for a compound that treats all types of cancer. Likewise, In re Cartright, 49 USPQ2d 1464, states: “Moreover, we have not been shown that one of ordinary skill would necessarily conclude from the information expressly disclosed by the written description that the active ingredient” does what the specification surmises that it does. That is exactly the case here. Moreover, even if Applicant’s assertion that cancer in general could be treated with these compounds were plausible -- which it is not --, that “plausible” would not suffice, as was stated in Rasmusson v. SmithKline Beecham Corp., 75 USPQ2d 1297, 1301: “If mere plausibility were the test for enablement under section 112, applicants could obtain patent rights to “inventions” consisting of little more than respectable guesses as to the likelihood of their success.
It is commonly known in the pharmaceutical arts that shape dictates function wherein drugs which have a shape complimentary to the protein target will bind and have an effect (this is often referred to simplistically as a “Lock and Key” model). Given the varied shape of protein targets in cancer, it is pure fantasy to speculate that a single drug with a single three-dimensional shape will bind all protein targets implicated in cancer therapy and have an effect in treating all forms of the disease. As such, at present the “silver bullet” drug therapy to treat all forms of cancer is elusive and such a therapy is not recognized in the art where the reality is that different forms of cancer require different drug therapies.
There do not appear to be examples in the prior art of inhibitors that are able to treat all cancers, or even most cancers. Regarding closely related tetrazine based cancer inhibitors, Stevens et al.1 teach analogs of formula (1):
PNG
media_image3.png
161
172
media_image3.png
Greyscale
, see Figure 1, page 5847 and Table 1 on page 5848. Stevens et al. demonstrated that CCRG 81045, wherein R is CH3, was an effective treatment for lymphoma, leukemia, sarcoma, melanoma and plasmacytoma in in vivo murine tumor models. See page 5850, Table 3, as well as Table 4 on page 5851.
Level of ordinary skill in the art:
An ordinary artisan in the area of drug development would have experience in synthesizing chemical compounds for particular activities. The synthesis of new drug candidates, while complex, is routine in the art. The process of finding new drugs that have in vitro activity against a particular biological target (i.e., receptor, enzyme, etc.) is well known. Additionally, while high throughput screening assays can be employed, developing a therapeutic method, as claimed, prior to synthesizing and testing compounds is generally not well-known or routine, given the complexity of certain biological systems.
The amount of direction provided and working examples:
Applicant demonstrates inhibitory activity in MGMT deficient cells using Compound I-1,
PNG
media_image1.png
152
257
media_image1.png
Greyscale
, among others in the assay beginning on page 149, with results shown in Table 6. Table 8 on page 159 shows results of compound I-1’s anticancer activity in MGMT deficient cells, as well as the assay described on page 188 wherein compound I-1 was tested for anti-cancer activity in MGMT deficient LN229 glioblastoma cells. Table 12 beginning on page 178, however, illustrates results wherein Compound I-1 was not able to provide any anti-cancer effects. Table 12 appears to constitute roughly half of the cancer cell lines tested.
No examples have been provided that would enable the instantly disclosed compounds for preventing or treating cancer generally, as claimed in instant claims 44 and 45.
Quantity of experimentation needed to use the invention
The quantity of experimentation needed is undue experimentation. A person having ordinary skill in the art would need not only to identify and/or develop metrics to be able to investigate the efficacy of the disclosed compounds in the treatment of cancer generally, but would also need to evaluate the disclosed compounds, with no assurance of success.
While Applicant has disclosed several hundred examples testing compound I-1 in cancer cell lines, the efficacy of the instantly claimed compounds in treating cancer generally has not been demonstrated. For instance, Applicant reports that Table 12 illustrates results wherein compound I-1 did not appear to have any anti-cancer effect at all. The utility thereof would not have been readily recognized by a person having ordinary skill in the art at the time of filing, as distinct cancers have mutually exclusive etiologies. The examples disclosed in the application are not sufficient to overcome the unpredictability of treating cancer generally.
A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.
Genentech Inc. V Novo Nordisk A/S (CAFC) 42 USPQ 2d 1001 states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “patent protection is granted in return for enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”. Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, a person having ordinary skill in the art would have to engage in undue experimentation to determine the efficacy of disclosed compounds in treating cancer, with no assurance of success.
Applicant may amend claims 44 and 45, for example, as follows:
“A method of treating MGMT deficient cancer…”.
Claim Rejections - 35 USC § 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 39 is rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
The claim recites “The compound of claim 39”, which would make it dependent upon itself. The claim therefore has improper dependency. Applicant may overcome the rejection by, for instance, amending the claim to recite “The compound of claim
Allowable Subject Matter
The claims are free of the prior art.
The closest prior art is from Stevens et al. in “Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine” Cancer Research 47, 5846-5852, November 15, 1987.
Stevens et al. teach compound CCRG 81045, see Figure 3 on page 5851:
PNG
media_image4.png
179
221
media_image4.png
Greyscale
, and related analogs of formula (1):
PNG
media_image3.png
161
172
media_image3.png
Greyscale
, see Figure 1, page 5847 and Table 1 on page 5848. The compounds of the prior art differ from instant Formula I-aa,
PNG
media_image5.png
153
191
media_image5.png
Greyscale
since R of the prior art compounds is not embraced by the X-O-R2 group of the present claims. Therefore, the compounds/methods of the instant application are both novel and nonobvious. Further, there is no suggestion or motivation that it would have been obvious to a skilled artisan to modify the referenced compounds in such a way as to identify the presently claimed compounds and expect the compounds to still treat cancer. Thus the claims are free of the prior art.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jalisa H. Ferguson whose telephone number is (703)756-1489. The examiner can normally be reached Monday - Friday 9:00am - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/J.H.F./Examiner, Art Unit 1626
/KAMAL A SAEED/Primary Examiner, Art Unit 1626
1 Stevens et al. “Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine” Cancer Research 47, 5846-5852, November 15, 1987.